secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001104659-26-020108
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026
--------------------------------------------------------------------------------

- Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.
- Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.
- GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.
- CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.
- EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/0001104659-26-020108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-020108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer